Logo Logo Logo
  • Company


    • Company Overview


    • Board of Directors


    • Executive Team


    • Advisory Board
  • Pipeline


    • Product Overview


    • AR-301 (Salvecin®)


    • AR-320 (Suvratoxumab)


    • AR-501 (Panaecin™)


    • AR-712 (COVID-19 mAb)


    • AR-701 (COVID-19 mAb)

    • Preclinical


      • AR-401

    • Out-licensed Products


      • AR-105 (Aerucin®)


      • AR-101 (Aerumab™)


      • AR-201
  • TECHNOLOGY


    • Technology Overview


    • APEXTM


    • MabIgX®


    • Therapeutic Targets


      • HAP / VAP


      • VAP Prevention


      • Cystic Fibrosis


      • COVID-19 Disease
  • Investors
    • Welcome
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
      • Analyst Coverage
    • Events and Webcasts
    • Publications and Posters
    • Investor alerts
    • Investor Inquiries
  • Contact Us


    • Contact Us


    • Careers
  • Company


    • Company Overview


    • Board of Directors


    • Executive Team


    • Advisory Board
  • Pipeline


    • Product Overview


    • AR-301 (Tosatoxumab)


    • AR-320 (Suvratoxumab)


    • AR-501 (Panaecin™)


    • AR-712 (COVID-19 mAb)


    • AR-701 (COVID-19 mAb)

    • Preclinical



      • AR-401

    • Out-licensed Products



      • AR-105 (Aerucin®)


      • AR-101 (AerumabTM)


      • AR-201
  • TECHNOLOGY


    • Overview


    • MabIgX®


    • Therapeutic Targets



      • HAP / VAP


      • VAP Prevention


      • Cystic Fibrosis


      • COVID-19 Disease
  • Investors
    • Welcome
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
      • Analyst Coverage
    • Events and Webcasts
    • Publications and Posters
    • Investor alerts
    • Investor Inquiries
  • Contact Us


    • Contact Us


    • Careers
Search:
 



Investors

Aridis Pharmaceuticals
YearTrailing 12-MonthsCalendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2016Calendar Year 2015Calendar Year 2014
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesJun 8, 2022Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.

CONTACT US

Aridis Pharmaceuticals Inc.
983 University Ave Suite B
Los Gatos, CA 95032
Phone: 408-385-1742
Fax: 408-960-3822

 

ADDITIONAL INFORMATION

Site Map
Privacy Policy
Financial Conflict of Interest Policy